CBP-174 is under clinical development by Suzhou Connect Biopharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CBP-174’s likelihood of approval (LoA) and phase transition for Atopic Dermatitis (Atopic Eczema) took place on 20 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CBP-174 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CBP-174 overview

CBP-174 is under development for the treatment of pruritis in atopic dermatitis and pruritus associated with atopic dermatitis. It is administered orally. It is a small molecule which targets histamine H3 receptor. It was also under development for allergic rhinitis (nasal congestion due to allergy).

Suzhou Connect Biopharmaceuticals overview

Suzhou Connect Biopharmaceuticals (Connect Biopharmaceuticals) discovers and develops next-generation immune modulators for the treatment of autoimmune diseases and inflammation. The company’s pipeline Product portfolio includes CBP-307 is an orally-active small molecule used for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD); CBP-201 is an antibody for asthma and atopic dermatitis; and CBP-174 is a small molecule inhibitor for the treatment of chronic skin inflammation. It utilizes T cell modulation technology platform for developing their products. Connect Biopharmaceuticals serves in the therapeutic areas of inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases. The company seeks to collaborate with pharmaceutical companies to develop and commercialize their products both inside and outside China. Connect Biopharmaceuticals is headquartered in Taicang, Jiangsu, China.

Quick View CBP-174 LOA Data

Report Segments
  • Innovator
Drug Name
  • CBP-174
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.